Ad
related to: new cancer pill
Search results
Results from the WOW.Com Content Network
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors.
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. [ 1 ] [ 5 ] [ 7 ] It is an inhibitor of tropomyosin kinase receptors TrkA , TrkB , and TrkC . [ 8 ] [ 9 ] [ 10 ] It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Walker’s regular injections may soon come to an end, thanks to a pill developed across the street from the hospital in Donald McDonnell’s cancer biology lab. The Food and Drug Administration ...
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Capivasertib, sold under the brand name Truqap, is an anti-cancer medication used for the treatment of breast cancer. [4] [7] It is taken by mouth.[4]The most common adverse reactions include diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides ...
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [5] [6] [10] Dostarlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.
In June 2024, the US FDA granted accelerated approval to adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. [10] [11]
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials. In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12]
Ad
related to: new cancer pill